Why the study?
Does montelukast increase antidepressant medication dispensing rates compared to fluticasone or LABA/ICS in patients initiating treatment?
Does montelukast increase antidepressant medication dispensing rates compared to fluticasone or LABA/ICS in patients initiating treatment?
Initiation of montelukast is not specifically associated with an increase in psychiatric adverse effects compared to other asthma/allergy medications.
Answers are grounded in this paper and cite their sources.
No montelukast-specific rise in antidepressant dispensing versus comparators; supports similar monitoring across therapies but leaves causality open.
Small increases in antidepressant medication dispensing rates occurred after initiating montelukast. However, similar increases were observed in the fluticasone and LABA/ICS comparison groups. The results of this study cannot support a specific association between initiation of montelukast treatment and an increase in psychiatric adverse effects.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: